API
ALNY icon

Advisor Partners II’s Alnylam Pharmaceuticals ALNY Stock Holding History

Advisor Partners II’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$292K Buy
1,646
+338
+26% +$64.5K 0.01% 974
2023
Q2 		$248K Buy
+1,308
New +$259K 0.01% 892
2023
Q1 		– Sell
-1,086
Closed -$258K – 1005
2022
Q4 		$258K Buy
+1,086
New +$232K 0.02% 747

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Advisor Partners II's ALNY Position: Q3 2023 in Review

Advisor Partners II increased its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q3 2023, buying an estimated $64.5K and bringing the position to 1,646 shares worth $292K. The position accounts for 0.01% of the portfolio, ranked #974.

Advisor Partners II first reported a position in ALNY in Q4 2022 and has held it in 3 quarters since. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • Advisor Partners II held 1,646 shares of Alnylam Pharmaceuticals worth $292K as of Q3 2023.
  • Advisor Partners II bought 338 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $64.5K.
  • Alnylam Pharmaceuticals made up 0.01% of Advisor Partners II's portfolio in Q3 2023, its #974 holding.
  • Advisor Partners II first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • 453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Advisor Partners II's 13F filing for Q3 2023, filed 26 Oct 2023.